Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis Psychedelics
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Core One Labs Inc
Bullboard Posts
User Avatar Image
(6)
•••
Comment by Leafs4Lifeon Sep 27, 2017 2:03pm
135 Views
Post# 26749368

RE:RE:RE:Here's sprinkle of good news to go with all the bad

RE:RE:RE:Here's sprinkle of good news to go with all the bad
StockMasterGods wrote: Leafs after you sell your LDS you may want to look at RVV.  Have a look at the news today.  It has much more upside than LDS.



Doesn't their cash position worry you? They had 2.2M at the end of the last quarter, lost 2.7 in 2016. Lost 1.6 million in the last 9 months (400k in the last quarter).  And they generate no revenue. 

I have only looked at the financials and news releases for 10 mins but it seems like the company is depending on FDA approval for drugs to send it to the moon (which could happen, I'm definitely no expert in that field). But that doesn't happen overnight.  How do they generate adequate revenue to keep the company afloat until the drugs are approved?

That's my 10 min analysis.  


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities